Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|17|4|297-302

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.17, Iss.4, 2017-11, pp. : 297-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The incretin system in the management of type 2 diabetes mellitus

By Stephens Jeffrey W  

Clinical Medicine, Vol. 10, Iss. 5, 2010-10 ,pp. : 491-495

Royal College Of Physicians

Access to resources Recommend Favorite

Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo  

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite

Incretin Mimetics Target Novel Pathways to Treat Type 2 Diabetes

By  

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 4, 2004-09 ,pp. : 18-22

Adis International

Access to resources Recommend Favorite

Fasiglifam as a new potential treatment option for patients with type 2 diabetes

By Kaku Kohei  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 18, 2013-12 ,pp. : 2591-2600

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

By Rajagopalan R.   Perez A.   Ye Z.   Khan M.   Murray F.T.  

Drugs & Aging, Vol. 21, Iss. 4, 2004-01 ,pp. : 259-271

Adis International

Access to resources Recommend Favorite